Increased Intestinal Permeability and Decreased Resiliency of the Intestinal Barrier in Alcoholic Liver Disease

Clin Transl Gastroenterol. 2024 Apr 1;15(4):e00689. doi: 10.14309/ctg.0000000000000689.

Abstract

Introduction: Only 20%-30% of individuals with alcohol use disorder (AUD) develop alcoholic liver disease (ALD). While the development of gut-derived endotoxemia is understood to be a required cofactor, increased intestinal permeability in ALD is not completely understood.

Methods: We recruited 178 subjects-58 healthy controls (HCs), 32 with ALD, 53 with AUD but no liver disease (ALC), and 35 with metabolic dysfunction-associated steatotic liver disease (MASLD). Intestinal permeability was assessed by a sugar cocktail as a percentage of oral dose. The permeability test was repeated after an aspirin challenge in a subset.

Results: Five-hour urinary lactulose/mannitol ratio (primarily representing small intestinal permeability) was not statistically different in HC, ALC, ALD, and MASLD groups ( P = 0.40). Twenty-four-hour urinary sucralose (representing whole gut permeability) was increased in ALD ( F = 5.3, P < 0.01) and distinguished ALD from ALC; 24-hour sucralose/lactulose ratio (primarily representing colon permeability) separated the ALD group ( F = 10.2, P < 0.01) from the MASLD group. After aspirin challenge, intestinal permeability increased in all groups and ALD had the largest increase.

Discussion: In a group of patients, we confirmed that (i) the ALD group has increased intestinal permeability compared with the HC, ALC, or MASLD group. In addition, because small bowel permeability (lactulose/mannitol ratio) is normal, the disruption of intestinal barrier seems to be primarily in the large intestine; (ii) decreased resiliency of intestinal barrier to injurious agents (such as NSAID) might be the mechanism for gut leak in subset of AUD who develop ALD.

Trial registration: ClinicalTrials.gov NCT05428072.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Alcoholism / complications
  • Alcoholism / metabolism
  • Aspirin / administration & dosage
  • Case-Control Studies
  • Female
  • Humans
  • Intestinal Absorption / drug effects
  • Intestinal Barrier Function
  • Intestinal Mucosa* / metabolism
  • Intestinal Mucosa* / pathology
  • Lactulose* / administration & dosage
  • Lactulose* / urine
  • Liver Diseases, Alcoholic* / metabolism
  • Male
  • Mannitol* / administration & dosage
  • Mannitol* / urine
  • Middle Aged
  • Permeability*
  • Sucrose / administration & dosage
  • Sucrose / analogs & derivatives*

Substances

  • Lactulose
  • Mannitol
  • Aspirin
  • Sucrose
  • trichlorosucrose

Associated data

  • ClinicalTrials.gov/NCT05428072